Abstract
Shigellosis, acute inflammatory bacillary dysentery diseases, is an important agent in the mortality of children in developing countries. Annually 165 million people are being infected leading to 1.2 million deaths around the world. Although vaccination appears to be the only rational prophylactic approach to control shigellosis, currently, there is no safe and efficacious vaccine available in the market. Here in this study, we investigated the protection conferred by a new vaccine based on nanoparticles containing outer membrane vesicles (OMVs) of Shigella sonnei in an experimental model of shigellosis in mice. OMVs extracted by deoxycholate detergent were encapsulated in chitosan-TPP nanoparticles prepared by an ion gelation method and coated with an enteric polymer (NP-OMVs). NP-OMVs were spherical and homogeneous with a mean size of 344.7 nm (PdI = 0.2). BALB/c mice (females, 9-week-old, 25 ± 1 g) were immunized intraperitoneally (i.p.) with 20 µg of OMVs or by intragastric route (i.g.) with 50 µg of free or encapsulated OMVs. The protein concentrations of OMVs were 0.65 mg/mL and 1.02 mg/mL for bacteria grown at 37 ̊C and 42 ̊C respectively. OMVs loaded into nanoparticles were homogeneous and spherical, with a size of 344 nm. The encapsulation efficiency of NP was 85%. Antibody titers in immunized mice sera after 78 days revealed a persistent immune response. Free OMVs were able to protect against infection when it was administered by the intraperitoneal route. Oral administration of NP-OMVs showed better protection whereas free OMVs did not protect against infection. The results obtained in this research place OMVs among promising candidates to be used for vaccination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- OMVs:
-
Outer membrane vesicles
- NP-OMVs:
-
Nanoparticle-outer membrane vesicles
- i.p.:
-
Intraperitoneal
- i.g.:
-
Intragastric
- CS:
-
Chitosan
- LPS:
-
Lipopolysaccharide
- LB:
-
Luria-Bertani
- DLS:
-
Dynamic light scattering
- RT:
-
Room temperature
- IpaD:
-
Invasion plasmid antigen D
- nOMVs:
-
Normal OMVs
- sOMVs:
-
Stress OMVs
- TEM:
-
Transmission Electron Microscopy
- WHO:
-
World Health Organization
- Eu:
-
Eudragit
References
Acevedo R, Fernandez S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, Rosenqvist E, Campa C, Cardoso D, Garcia L (2014) Bacterial outer membrane vesicles and vaccine applications. Front Immunol 5:121. https://doi.org/10.3389/fimmu.2014.00121
Adriani R, Gargari SLM, Nazarian S, Sarvary S, Noroozi N (2018) Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions. Vaccine 36:322–330. https://doi.org/10.1016/j.vaccine.2017.09.004
Ashkenazi S, Cohen D (2013) An update on vaccines against Shigella. Therapeutic advances in vaccines 1:113–123. https://doi.org/10.1177/2051013613500428
Bishop AL, Schild S, Patimalla B, Klein B, Camilli A (2010) Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by anti lipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun 78:4402–4420. https://doi.org/10.1128/IAI.00398-10
Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 1:117–128. https://doi.org/10.2147/nano.2006.1.2.117
Camacho A, Souza-Reboucas J, Irache JM, Gamazo C (2013) Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies. Methods 60:264–268. https://doi.org/10.1016/j.ymeth.2012.09.008
Chen WH, Kotloff KL (2016) Shigella vaccine development: finding the path of least resistance. Clin Vaccine Immunol 23:904–907. https://doi.org/10.1128/CVI.00444-16
Collins BS (2011) Gram-negative outer membrane vesicles in vaccine development. Discov Med 12:7–15
Delbaz SA, Siadat SD, Aghasadeghi MR, Piryaie M, Peerayeh SN, Mousavi SF, Moshiri A, Sadat SM, Zangeneh M, Nejati M (2013) Biological and immunological evaluation of Neisseria meningitidis serogroup A outer Membrane vesicle as vaccine candidates. Jundishapur J Microbiol 6:1–6. https://doi.org/10.5812/jjm.5007
Farris E, Brown DM, Ramer-Tait AE, Pannier AK (2016) Micro-and nanoparticles for DNA vaccine delivery. Exp Biol Med (Maywood) 241:919–929. https://doi.org/10.1177/1535370216643771
Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E(2001) Outer membrane protein vesicle vaccines for meningococcal disease, In Meningococcal vaccines. Springer, pp. 81–107. https://doi.org/10.1385/1-59259-148-5:81
Fulsundar S, Harms K, Flaten GE, Johnsen PJ, Chopade BA, Nielsen KM (2014) Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation. Appl Environ Microbiol 80:3469–3483. https://doi.org/10.1128/AEM.04248-13
Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, Rosenqvist E (2009) Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27:B3–B12. https://doi.org/10.1016/j.vaccine.2009.04.071
Kadurugamuwa JL, Beveridge TJ (1998) Delivery of the Non-Membrane-Permeative Antibiotic Gentamicin into Mammalian Cells by Using Shigella flexneri Membrane Vesicles. Antimicrob Agents Chemother 42:1476–1483. https://doi.org/10.1128/AAC.42.6.1476
Kalam MA, Khan AA, Alshamsan A (2017) Non-invasive administration of biodegradable nano-carrier vaccines. Am J Transl Res 9:15–35
Keenan JI, Rijpkema SG, Durrani Z, Roake JA (2003) Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens. FEMS Immunol Med Microbiol 36:199–205. https://doi.org/10.1016/S0928-8244(03)00091-9
Kotton CN, Hohmann EL (2004) Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun 72:5535–5547. https://doi.org/10.1128/IAI.72.10.5535-5547.2004
Kulp A, Kuehn MJ (2010) Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 64:163–184. https://doi.org/10.1146/annurev.micro.091208.073413
Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB (2014) Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis 59:933–941. https://doi.org/10.1093/cid/ciu468
Lorenzo-Lamosa M, Remunan-Lopez C, Vila-Jato J, Alonso M (1998) Design of microencapsulated chitosan microspheres for colonic drug delivery. Journal Control Release 52:109–118. https://doi.org/10.1016/S0168-3659(97)00203-4
Mani S, Wierzba T, Walker RI (2016) Status of vaccine research and development for Shigella. Vaccine 34:2887–2894. https://doi.org/10.1016/j.vaccine.2016.02.075
Markwell MAK, Haas SM, Bieber L, Tolbert N (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206–210. https://doi.org/10.1016/0003-2697(78)90586-9
Mashburn-Warren L, Mclean R, Whiteley M (2008) Gram‐negative outer membrane vesicles: beyond the cell surface. Geobiology 6:214–219. https://doi.org/10.1111/j.1472-4669.2008.00157.x
Mitra S, Barman S, Nag D, Sinha R, Saha DR, Koley H (2012) Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. FEMS Immunol Med Microbiol 66:240–250. https://doi.org/10.1111/j.1574-695X.2012.01004.x
Norheim G, Tunheim G, Naess L, Kristiansen P, Caugant D, Rosenqvist E (2012) An Outer Membrane Vesicle Vaccine for Prevention of Serogroup A and W-135 Meningococcal Disease in the African Meningitis Belt. Scand J Immunol 76:99–107. https://doi.org/10.1111/j.1365-3083.2012.02709.x
Noroozi N, Gargari SLM, Nazarian S, Sarvary S, Rezaei Adriani R (2018) Immunogenicity of enterotoxigenic Escherichia coli outer membrane vesicles encapsulated in chitosan nanoparticles. Iran J Basic Med Sci 21:284–291. https://doi.org/10.22038/ijbms.2018.25886.6371
Onishi H, Oosegi T, Machida Y, McGinity JW (2007) Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres. Drug Dev Ind Pharm 33:848–854. https://doi.org/10.1080/03639040701377904
Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9:1095–1107. https://doi.org/10.1586/erv.10.89
Park K (2014) Controlled drug delivery systems: past forward and future back. Journal Control Release 190:3–8. https://doi.org/10.1016/j.jconrel.2014.03.054
Prasanth V, Jayaprakash R, Mathew ST (2012) Colon specific drug delivery systems: a review on various pharmaceutical approaches. J Appl Pharm Sci 2:163–169. doi:https://doi.org/10.5001/omj.2010.24
Puzari M, Sharma M, Chetia P (2018) Emergence of antibiotic-resistant Shigella species: A matter of concern. J Infect Public Health 11:451–454. https://doi.org/10.1016/j.jiph.2017.09.025
Quan J-S, Jiang H-L, Kim E-M, Jeong H-J, Choi Y-J, Guo D-D, Yoo M-K, Lee H-G, Cho C-S (2008) pH-sensitive and mucoadhesive thiolated Eudragit-coated chitosan microspheres. Int J Pharm 359:205–210. https://doi.org/10.1016/j.ijpharm.2008.04.003
Sanders H, Feavers IM (2011) Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines 10:323–334. https://doi.org/10.1586/erv.11.10
Simerska P, Moyle PM, Olive C, Toth I (2009) Oral vaccine delivery-new strategies and technologies. Curr Drug Deliv 6:347–358. https://doi.org/10.2174/156720109789000537
Thompson CN, Duy PT, Baker S (2015) The rising dominance of Shigella sonnei: an intercontinental shift in the etiology of bacillary dysentery. PLoS Negl Trop Dis 9:e0003708. https://doi.org/10.1371/journal.pntd.0003708
Van de Waterbeemd B, Streefland M, Van der Ley P, Zomer B, Van Dijken H, Martens D, Wijffels R, Van der Pol L (2010) Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28:4810–4816. https://doi.org/10.1016/j.vaccine.2010.04.082
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1459–1544. https://doi.org/10.1016/S0140-6736(16)31012-1
Xia Y, Fan Q, Hao D, Wu J, Ma G, Su Z (2015) Chitosan-based mucosal adjuvants: Sunrise on the ocean. Vaccine 33:5997–6010. https://doi.org/10.1016/j.vaccine.2015.07.101
Yang S-C, Hung C-F, Aljuffali IA, Fang J-Y (2015) The roles of the virulence factor IpaB in Shigella spp. in the escape from immune cells and invasion of epithelial cells. Microbiol Res 181:43–51. https://doi.org/10.1016/j.micres.2015.08.006
Zhang H-l, Wu S-h, Tao Y, Zang L-q, Su Z-q (2010) Preparation and characterization of water-soluble chitosan nanoparticles as protein delivery system. J Nanomater 2010: 1. https://doi.org/10.1155/2010/898910
Acknowledgements
The authors wish to thank Shahed University for supporting this work.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sarvary, S., Mousavi Gargari, S.L., Nazarian, S. et al. Immunogenicity of Shigella sonnei outer membrane vesicles extracted in different environmental conditions. Biologia 76, 721–728 (2021). https://doi.org/10.2478/s11756-020-00606-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11756-020-00606-8